重组人血管内皮抑制素注射液联合同步放化疗对不可切除Ⅲ期非小细胞肺癌患者血清血管内皮生长因子水平及预后的影响

Effects of Recombinant human endostatin injection combined with concurrent radiotherapy and chemotherapy on the level of vascular endothelial growth factor and prognosis in non-resectable stage Ⅲ non-small cell lung cancer patients

目的探索重组人血管内皮抑制素注射液联合同步放化疗对不可切除Ⅲ期非小细胞肺癌(nonsmall cell lung cancer,NSCLC)患者血清血管内皮生长因子(vascular endothelial growth factor,VEGF)及预后的影响。方法选取2015年3月至2015年12月本院收治的不可切除Ⅲ期NSCLC患者105例为研究对象。按照治疗方式的不同将入选患者分为观察组(52例)和对照组(53例)。观察组患者采用重组人血管内皮抑制素注射液联合同步放化疗治疗,对照组患者采用同步放化疗治疗。比较两组患者治疗前后血清VEGF水平、治疗效果、预后及不良反应发生情况。结果治疗前,两组患者VEGF水平比较无显著差异(P>0.05)。治疗后1周和2周,两组患者VEGF水平较治疗前均显著升高(P<0.05),观察组患者VEGF水平低于对照组(P<0.05)。观察组患者治疗客观缓解率、1年生存率及1年肿瘤无进展生存率均显著高于对照组(P<0.05)。两组患者各不良反应发生率比较均无显著差异(P>0.05)。结论重组人血管内皮抑制素注射液联合同步放化疗治疗不可切除Ⅲ期NSCLC,可以显著降低患者血清VEGF水平,提高肿瘤缓解率,改善患者预后,不增加不良反应,安全性较好。

Objective To evaluate the effects of Recombinant human endostatin injection combined with concurrent radiotherapy and chemotherapy on the level of serum vascular endothelial growth factor （VEGF） and prognosis in non-resectable stage Ⅲ non-small cell lung cancer （NSCLC） patients. Method 105 patients with no-resectable stage Ⅲ NSCLC from March 2015 to December 2015 in our hospital were selected as the research subjects, they were divided into observation group （n = 52） and control group （n = 53） according to the choice of treatment. Patients in observation group were treated with Recombinant human endostatin injection combined with concurrent chemoradiotherapy and chemotherapy, patients in control group were treated with concurrent chemoradiotherapy and chemotherapy. The VEGF levels before and after treatment, treatment effects, prognosis and adverse reactions were compared between the two groups. Result There was no significant difference in VEGF between the two groups before treatment （P 〉 0.05）. After 1 week and 2 weeks treatment, the levels of VEGF were significantly higher than those before treatment in both groups （P 〈 0.05）. The level of VEGF in observation group was significantly lower than that of control group after treatment （P 〈 0.05）. The objective response rate, 1-year survival rate and 1-year progression-free survival rate of observation group were significantly higher than those of control group （P 〈 0.05）. There was no significant difference in the incidence of adverse reactions between the two groups （P 〉 0.05）. Conclusion Recombinant human endostatin injection combined with concurrent radiotherapy and chemotherapy in the treatment of non-resectable stage Ⅲ NSCLC can significantly reduce the level of serum VEGF, improve the tumor remission rate and prognosis, while not increasing the incidence of adverse reactions.